JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models

被引:0
|
作者
Manish R. Patel
Alexander Dash
Blake A. Jacobson
Yan Ji
Daniel Baumann
Kareem Ismail
Robert A. Kratzke
机构
[1] University of Minnesota Medical School,Department of Medicine, Division of Hematology, Oncology, and Transplantation
[2] Macalester College,Department of Biology
[3] Regions Hospital,Health Partners
来源
Cancer Gene Therapy | 2019年 / 26卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The concept of using viruses to treat cancer has now shown proof of concept in several recent clinical trials, leading to the first FDA approval of virotherapy for melanoma last year. Vesicular stomatitis virus (VSV) is a promising oncolytic virus that has inhibitory effects on a number of cancer types including non-small cell lung cancer. One of the major mechanisms of resistance to VSV infection is the type I interferon (IFN) response, leading to the development of VSV expressing IFNβ which will lead to resistance of viral replication in normal cells which have intact IFN signaling but allow replication in cancer cells with defective IFNβ signaling. However, some cancer cells have intact or partially intact IFN signaling pathways leading to resistance to virotherapy. Here we utilized JAK/STAT inhibitor, ruxolitinib, in combination with VSV-IFNβ to see if inhibition of JAK/STAT signaling will enhance VSV-IFNβ therapy for lung cancer. We used five human and two murine NSCLC cell lines in vitro, and the combination treatment was assayed for cytotoxicity. We performed western blots on treated cells to see the effects of ruxolitinib on JAK/STAT signaling and PDL-1 expression in treated cells. Finally, the combination of VSV-IFNβ and ruxolitinib was tested in an immune competent murine model of NSCLC. Ruxolitinib enhanced virotherapy in resistant and sensitive NSCLC cells. The addition of ruxolitinib inhibited STAT1 phosphorylation and to a lesser extent STAT3 phosphorylation. Ruxolitinib treatment prevented NSCLC cells from enhancing PDL-1 expression in response to virotherapy. Combination ruxolitinib and VSV-IFNβ therapy resulted in a trend toward improved survival of mice without substantially effecting PDL-1 levels or levels of immune infiltration into the tumor. These results support further clinical evaluation of the combination of JAK/STAT inhibition with virotherapy.
引用
收藏
页码:411 / 418
页数:7
相关论文
共 50 条
  • [1] JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models
    Patel, Manish R. k
    Dash, Alexander
    Jacobson, Blake A.
    Ji, Yan
    Baumann, Daniel
    Ismail, Kareem
    Kratzke, Robert A.
    CANCER GENE THERAPY, 2019, 26 (11-12) : 411 - 418
  • [2] Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC
    Hu, Yuan
    Hong, Yin
    Xu, YuanJie
    Liu, Ping
    Guo, Dai-Hong
    Chen, Yibang
    APOPTOSIS, 2014, 19 (11) : 1627 - 1636
  • [3] Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC
    Yuan Hu
    Yin Hong
    YuanJie Xu
    Ping Liu
    Dai-Hong Guo
    Yibang Chen
    Apoptosis, 2014, 19 : 1627 - 1636
  • [4] MET inhibition enhances the effect of radiation in MET dysregulated non-small cell lung cancer models
    Ramesh, Shrey K.
    Javeri, Saahil N.
    Nickel, Kwangok P.
    Cifci, Ahmet
    Minne, Rachel L.
    Kimple, Randall J.
    Baschnagel, Andrew M.
    CANCER RESEARCH, 2023, 83 (07)
  • [5] FGFR Inhibition Enhances Sensitivity to Radiation in Non-Small Cell Lung Cancer
    SenthilKumar, Gopika
    Fisher, Michael M.
    Skiba, Justin H.
    Miller, Margot C.
    Brennan, Sean R.
    Kaushik, Saakshi
    Bradley, Samantha T.
    Longhurst, Colin A.
    Buehler, Darya
    Nickel, Kwangok P.
    Iyer, Gopal
    Kimple, Randall J.
    Baschnagel, Andrew M.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (06) : 1255 - 1265
  • [6] VIROTHERAPY WITH VSV-IFNB FOR NON-SMALL CELL LUNG CANCER
    Patel, Manish R.
    Jacobson, Blake A.
    Xiong, Kerry
    Tang, Shaogeng
    Wang, Hengbing
    Ji, Yan
    Kratzke, Andrea
    Kratzke, Robert A.
    ANTICANCER RESEARCH, 2014, 34 (10) : 6106 - 6106
  • [7] Navitoclax Enhances the Efficacy of Taxanes in Non-Small Cell Lung Cancer Models
    Tan, Nguyen
    Malek, Mehnaz
    Zha, Jiping
    Yue, Peng
    Kassees, Robert
    Berry, Leanne
    Fairbrother, Wayne J.
    Sampath, Deepak
    Belmont, Lisa D.
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1394 - 1404
  • [8] Inhibition of FASN expression enhances radiosensitivity in human non-small cell lung cancer
    Zhan, Ning
    Li, Bin
    Xu, Xiangying
    Xu, Jianyu
    Hu, Songliu
    ONCOLOGY LETTERS, 2018, 15 (04) : 4578 - 4584
  • [9] MEK inhibition in non-small cell lung cancer
    Stinchcombe, Thomas E.
    Johnson, Gary L.
    LUNG CANCER, 2014, 86 (02) : 121 - 125
  • [10] Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients
    Mathew, Divij
    Marmarelis, Melina E.
    Foley, Caitlin
    Bauml, Joshua M.
    Ye, Darwin
    Ghinnagow, Reem
    Ngiow, Shin Foong
    Klapholz, Max
    Jun, Soyeong
    Zhang, Zhaojun
    Zorc, Robert
    Davis, Christiana W.
    Diehn, Maximillian
    Giles, Josephine R.
    Huang, Alexander C.
    Hwang, Wei-Ting
    Zhang, Nancy R.
    Schoenfeld, Adam J.
    Carpenter, Erica L.
    Langer, Corey J.
    Wherry, E. John
    Minn, Andy J.
    SCIENCE, 2024, 384 (6702) : 1314 - +